History

  • Step 1
    Foundation of JETEMA
  • Step 2
    Filler business development
    2015.03
    • HA filler plant establishment
    2017.04
    • e.p.t.q.® (HA filler) launched in Korea
    2017.09
    • e.p.t.q.® with lidocaine launched in Korea
  • Step 3
    Botulinum toxin and lifting thread business development / KOSDAQ listing
    2018.12
    • epiticon® Original (PDO thread) launched in Korea
    • epiticon® Original world patent application
    2019.02
    • In-licensing commercial botulinum toxin strains
      type A, B, and E
    2019.03
    • Botulinum toxin plant establishment
    2019.11
    • KOSDAQ listing
    2020.06
    • epiticon® Thin (PDO thread) launched in Korea
  • Step 4
    A leap forward as a global leader
    2020.01
    • CE approval for e.p.t.q.® with lidocaine
    2020.05
    • ANVISA approval for e.p.t.q.® with lidocaine
    2020.06
    • JETEMA botulinum toxin export license approval
    2021.05
    • Medicine research center establishment
    2021.06
    • Launched By.derm (Medical Device Cream) in Korea
    2021. 11
    • Established a local subsidiary in China
    2022. 02
    • Entered into out-licensing agreement with China for JETEMA THE TOXIN
    2022. 09
    • JETEMA GLOBAL moved to a new office in Pangyo
    2022. 12
    • Established a local subsidiary in the U.S.
    2023. 01
    • Launched EXO'LUTION (Skinbooster) in Korea
    • Approved Phase 1/2 Clinical Trial Plan for JETEMA THE TOXIN 100U (glabellar lines) in China
    2023. 03
    • Launched Lénafill (Hyaluronic Acid Filler) in Korea
    2023. 04
    • Established PDO suture factory
    2023. 07
    • Completed Phase 3 Clinical Trial for JETEMA THE TOXIN 100U (glabellar lines) in Korea
    2023. 10
    • Applied for Korea MFDS approval of JETEMA THE TOXIN
    2023. 11
    • Applied for Pre-IND meeting for Phase 2 waiver and Phase 3 initiation for JETEMA THE TOXIN 100U in China
    • Submitted Investigational New Drug (IND) application for Phase 2 Clinical Trial of JETEMA THE TOXIN 100U in the USA
    2023. 12
    • Approved IND for Phase 2 Clinical Trial of JETEMA THE TOXIN 100U in the USA
    • Awarded the "30 Million Dollar Export Tower" on the 60th Trade Day
    2024. 02
    • Signed a supply agreement for JETEMA THE TOXIN with a partner in Thailand
    2024. 03
    • Approved Phase 2 waiver and Phase 3 initiation for JETEMA THE TOXIN 100U in China
    2024. 04
    • Launched new HA (Hyaluronic Acid) filler "순수필"
    2024. 06
    • Completed Phase 1 Clinical Trial for JETEMA THE TOXIN 100U (glabellar lines) in China
    2024. 07
    • Launched new PN skin booster "prajué"
    2024. 07
    • Launched new PN skin booster "prajué"
    2024. 08
    • Launched new PLLA skin booster "Ecolla S"
    2024. 09
    • Completed Phase 1 Clinical Trial for JETEMA THE TOXIN (upper limb muscle spasticity) in Korea
    2024. 12
    • Obtained domestic marketing authorization (KFDA) for JETEMA THE TOXIN 100U
    2025. 03
    • Domestically launched JETEMA THE TOXIN 100U for glabellar lines
    2025. 04
    • Obtained NMPA (National Medical Products Administration) approval for e.p.t.q. S500 in China
    2025. 07
    • Approved Phase 3 Clinical Trial for new HA filler (nasolabial folds)
    2025. 10
    • Obtained medical device manufacturing license for CaHa filler (for export)
    2025. 12
    • Signed an exclusive supply agreement for e.p.t.q. Filler in Thailand